Search over 3,000 reports

    Invega Sustenna/Xeplion- Drug Insight, 2017

    Invega Sustenna/Xeplion- Drug Insight, 2017
    Date: Jan, 2018
    Type: Pharmaceutical Industry Report
    Pages: 35
    Geography: Global
    Delivery Timeline: 48 hours
    SKU: DIDI0179
    "Invega Sustenna/Xeplion - Drug Insight, 2018" report by DelveInsight provides comprehensive information of the drug, Invega Sustenna/Xeplion. It includes Invega Sustenna/Xeplion`s overview, mechanism, clinical trials, regulatory milestones, deals & partnerships. It further provides Invega Sustenna/Xeplion`s patents (US & EU)* and its API manufacturers details in the United States, Europe, China and India.* It also features the historical and forecasted sales of Invega Sustenna/Xeplion till 2020. The report also throws light on Invega Sustenna/Xeplion`s market competition and emerging therapies in the same space as Invega Sustenna/Xeplion. A SWOT analysis of Invega Sustenna/Xeplion is also featured.
    * Depending on information availability

    Methodology
    Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
    Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

    Scope of the report
    • A comprehensive product overview including product description, regulatory milestones, clinical trials, deals and partnerships, have been elaborated in this report
    • Patent information around Invega Sustenna/Xeplion in United States (US) and Europe (EU) has been highlighted
    • API manufacturers for Invega Sustenna/Xeplion in United States, Europe, China and India
    • The report contains historical and forecasted sales for Invega Sustenna/Xeplion till 2020
    • Comprehensive coverage of the emerging therapies (Phase III) in the space where Invega Sustenna/Xeplion operates including their product description, research and development activities, collaborations and licensing deals, drug mechanism and chemical information
    • The report also features the SWOT analysis of Invega Sustenna/Xeplion

    Reasons to Buy
    • Establish a comprehensive understanding of the drug, Invega Sustenna/Xeplion
    • Access to Invega Sustenna/Xeplion`s API manufacturers details to devise API procurement strategy for generic development
    • Plan developmental timelines around Invega Sustenna/Xeplion`s patents for the major markets- US and EU
    • Understand Invega Sustenna/Xeplion`s current and future growth through its historical and forecasted sales
    • Identify and understand the current in-market competitors for Invega Sustenna/Xeplion
    • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
    • Identify and plan ahead for prospective emerging players and their products operating in the same space as Invega Sustenna/Xeplion
    • Identify opportunities in the same area as Invega Sustenna/Xeplion with DelveInsight`s SWOT analysis
    1. Report Introduction
    2. Invega Sustenna/Xeplion - Overview
    • Product Description
    • Route of Synthesis
    • Mechanism of Action
    • Pharmacology
    • Pharmacodynamics
    • Pharmacokinetics
    • Adverse Reactions
    • Clinical Trials
    • Regulatory Milestones
    • Product Development Activities
    3. Global API Manufacturers
    • United States
    • Europe
    • China
    • India
    4. Product Details
    • United States
    • Europe
    5. Invega Sustenna/Xeplion Global Sales Assessment
    • Historical Global Sales
    • Forecasted Global Sales
    6. Patent Details
    7. Market Competition
    8. Emerging Therapies
    8.1. Drug name: Company name
    • Product Description
    • Research & Development
    • Product Development Activities
    Other product profiles in the detailed report…..
    9. SWOT Analysis
    Appendix
    Methodology
    Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer
    Note: Certain sections of the table of contents would vary according to the availability of information
    Table 1: Invega Sustenna/Xeplion, Description
    Table 2: API Manufacturers Region wise
    Table 3: API Manufacturers for United States
    Table 4: API Manufacturers for Europe
    Table 5: API Manufacturers for China
    Table 6: API Manufacturers for India
    Table 7: Invega Sustenna/Xeplion Product Details, United States
    Table 8: Invega Sustenna/Xeplion Product Details, Europe
    Table 9: Invega Sustenna/Xeplion, Historical Global Sales till 2017 (in million USD)
    Table 10: Invega Sustenna/Xeplion, Forecasted Global Sales from 2018-2020 (in million USD)
    Table 11: Patent Details: Invega Sustenna/Xeplion
    Table 12: Invega Sustenna/Xeplion Major Competitors
    Table 13: Emerging Therapies
    Figure 1: Invega Sustenna/Xeplion
    Figure 2: Invega Sustenna/Xeplion, Historical Global Sales till 2017 (in million USD)
    Figure 3: Invega Sustenna/Xeplion, Forecasted Global Sales from 2018-2020 (in million USD)
    Figure 4: Patent Details: Invega Sustenna/Xeplion
    Figure 5: API Manufacturers Region wise
    Invega Sustenna/Xeplion

    Invega Sustenna/Xeplion Marketed Drugs Overview

    Invega Sustenna/Xeplion Market Assessment

    Invega Sustenna/Xeplion API Manufacturers/ Active Pharmaceutical Ingredients Manufacturers

    Invega Sustenna/Xeplion US DMF

    Invega Sustenna/Xeplion US Drug Master Files

    Invega Sustenna/Xeplion Active Substance Master File/ EUDMF

    Invega Sustenna/Xeplion Generic players

    Invega Sustenna/Xeplion Patent Expiration

    Invega Sustenna/Xeplion Patent Exclusivity

    Invega Sustenna/Xeplion API Manufacturers

    Invega Sustenna/Xeplion Global Forecasted Sales Figure

    Invega Sustenna/Xeplion API Route of Synthesis

    Invega Sustenna/Xeplion Market sales

    Invega Sustenna/Xeplion SWOT Analysis

    Invega Sustenna/Xeplion Pipeline

    • Single User License
      (20% Off)
      $1,000.00
    • Site License
      (30% Off)
      $2,000.00
    • Global License
      (40% Off)
      $3,000.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap